Trial
NCT00582166
Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Wisconsin, Madison
Collaborators
Genentech, Inc.
Condition
Non-Hodgkin's Lymphoma
Intervention
Ibritumomab Tiuxetan (Zevalin) + Rituximab
Why stopped
See 'Limitations and Caveats' section
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-13